Nuvectis Pharma, Inc.
NVCT
$6.43
$0.6210.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.71% | 8.48% | -5.83% | -7.82% | 3.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.07% | 9.06% | -5.29% | -9.36% | -10.85% |
| Operating Income | -37.07% | -9.06% | 5.29% | 9.36% | 10.85% |
| Income Before Tax | -30.98% | -4.57% | 9.92% | 14.65% | 13.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.98% | -4.57% | 9.92% | 14.65% | 13.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.98% | -4.57% | 9.92% | 14.65% | 13.25% |
| EBIT | -37.07% | -9.06% | 5.29% | 9.36% | 10.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -16.11% | 10.19% | 19.95% | 22.34% | 21.00% |
| Normalized Basic EPS | -12.91% | 5.66% | 16.25% | 18.81% | 20.78% |
| EPS Diluted | -16.11% | 10.19% | 19.95% | 22.34% | 21.00% |
| Normalized Diluted EPS | -12.91% | 5.66% | 16.25% | 18.81% | 20.78% |
| Average Basic Shares Outstanding | 22.26% | 16.01% | 12.15% | 10.03% | 10.25% |
| Average Diluted Shares Outstanding | 22.26% | 16.01% | 12.15% | 10.03% | 10.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |